Comparison of the hormone receptors and HER-2 expressions between breast ductal carcinoma in situ and infiltrating ductal carcinoma

doi:10.3877/cma. j. issn.1674-0807.2013.02.005

Abstract

Abstract:

Objective

To study the differences of the hormone receptors and HER-2 expression and molecular typing between breast ductal carcinoma in situ (DCIS) and infiltrating ductal carcinoma (IDC)patients.

Methods

The specimens were collected from 52 cases of DCIS and 224 cases of IDC from March 2006 to September 2012. ER, PR and HER-2 were detected by immunohistochemical method, and Chi-square test was used to analyze the molecular typing of the two groups.

Results

ER positive expression rate in the IDC group (67.86%,152/224) was higher than that in the DCIS group (48.08%, 25/52)(χ²=7.18, P=0.01), while the HER-2 positive expression rate in the IDC group (54.02%,121/224) was lower than that in the DCIS group (73.08%,38/52)(χ²=6.28,P=0.01). PR expression showed no significant difference (χ²=1.39,P=0.24). The dominant molecular type was HER-2 positive in the DCIS group (44.23%, 23/52),luminal A in the IDC group (43.75%,98/224), which showed significant difference between the two groups(χ²=13.11,P=0.00).

Conclusion

The detection of ER, HER-2 expression and molecular typing in DCIS and IDC patients can provide important references to clinical diagnosis and individualized treatment.

Key words: breast neoplasms, hormone receptors, HER-2, molecular typing

Xiu-zhen QIAN, Yong-kun QIAN. Comparison of the hormone receptors and HER-2 expressions between breast ductal carcinoma in situ and infiltrating ductal carcinoma[J]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(02): 97-101.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2013.02.005

https://zhrxbzz.cma-cmc.com.cn/EN/Y2013/V07/I02/97

Figures/Tables 8

References 28

[1]	Cherubini M, Baxa P, Guarino G. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution[J]. Chir Ital,2002,54(4):423-428.
[2]	Riou G,Mathieu MC, Barrois M, et al. C-erbB-2(HER-2/neu)gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients[J].Int J Cancer,2001,95(4):266-270.
[3]	罗善山,陈俊强. 乳腺癌分子分型的研究进展[J]. 微创医学,2009,4(3):257-259.
[4]	刘新杰,周文斌,周冬仙,等. C-erbB-2, ER 及PR 表达在乳腺导管内癌与浸润性导管癌的对照研究[J]. 中国普通外科杂志,2008,17(12):1226-1228.
[5]	连臻强,张江宇,王颀,等. 乳腺导管内癌及其微浸润癌病理和生物学指标表达差异的临床意义[J/CD]. 中华乳腺病杂志:电子版,2011,5(4):419-425.
[6]	李世超,齐晓伟. 美国临床肿瘤学会和美国病理学家学会乳腺癌雌激素/孕激素受体免疫组化检测指南[J/CD]. 中华乳腺病杂志:电子版,2011,5(3):385-387.
[7]	吴世凯,宋三泰. 对乳腺癌雌孕激素受体检测的认识[J/CD]. 中华乳腺病杂志:电子版,2012,6(3):304-308.
[8]	Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor 2 testing in breast cancer[J]. Arch Pathol Lab Med,2007,131(1):18-43.
[9]	赵晶,付丽. 乳腺癌的分子分型[J/CD]. 中华乳腺病杂志:电子版,2009,3(2):195-203.
[10]	张伟欣,姜文玉,代文杰,等. 乳腺导管内癌临床特点与外科治疗的选择[J]. 中华内分泌外科杂志, 2012, 6(2):112-113,116.
[11]	Mylonas I, Makovitzky J, Jeschke U, et al. Expression of HER2/neu, steroid receptors(ER and PR), Ki67 and P53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ(DCIS) versus invasive breast cancer alone[J]. Anticancer Res,2005,25(3A):1719-1723.
[12]	罗文伟,任建强. C-erbB-2、P53、ER、PR 在乳腺癌中的表达和临床意义[J]. 医学信息,2011,24(6):3743-3744.
[13]	李文华,孙奇,覃希,等. ER、PR、C-erbB-2、HMFG 在乳腺癌组织中的表达及临床意义[J]. 山东医药, 2011, 51(47):54-56.
[14]	唐小慧. 雌激素受体、孕激素受体在乳腺癌中的表达及临床意义[J]. 现代中西医结合杂志,2010,19(32):4132-4133.
[15]	王雅杰. ER、PR 和HER-2 与乳腺癌个体化治疗[J]. 临床肿瘤学杂志,2010,15(2):97-100.
[16]	周东升,曾江正,胡敏,等. 乳腺侵润性导管癌中ER、PR 和Her-2、Ki-67、P53 的表达[J]. 中国医药指南,2012,10(17):276-277.
[17]	宋海云,陈登庭,邢鲁奇. 乳腺癌组织中ER、PR 及C-erb-2、p53 的表达变化及意义[J]. 山东医药,2010,50(3O):96-97.
[18]	李美蓉,范松青,张利群,等. 乳腺癌激素受体和癌基因的表达及临床意义[J]. 中国医师杂志,2006,8(1):34-37.
[19]	杨超,刘志英,肖刚,等. 乳腺导管内癌与浸润性导管癌激素受体表达比较[J]. 山东医药,2008,48(25):114.
[20]	徐嘉雯,张庆慧,孙晔,等. 乳腺导管内增生性病变及浸润性癌中雌激素受体亚型表达的比较性研究[J]. 山东大学学报(医学版),2008,46(1):72-75.
[21]	贾楠. 乳腺癌中DNA 甲基化与ER 和PR 及HER-2 表达的关系[J]. 医学综述,2010,16(20):3075-3077.
[22]	Beenken SW, Grizzle WE, Crowe DR, et al. Molecular biomarkers for breast cancer prognosis:coexpression of C-erbB-2 and P53[J]. Ann Surg,2001,233(5):630-638.
[23]	王雅杰,王宁. ER 及Her-2 对乳腺癌治疗策略的影响[J].中国癌症杂志,2010,20(10):721-725.
[24]	陆肖玮,马荣庚,朱云龙,等. 癌基因C-erbB-2、抗癌基因p53在乳腺癌中的表达及其意义[J]. 江苏临床医学杂志,2000,4(1):84-85.
[25]	罗玉莲,吴强. P185 和P16 在乳腺癌中的表达及其意义[J]. 安徽医科大学学报,2001,36(1):24-26.
[26]	封敏,黄艳春,赵锋. 乳腺癌组织中C-erbB-2 基因蛋白的表达及其意义[J]. 新疆医科大学学报,2006,29(10):976-978.
[27]	Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature,2000,406(6797):747-752.
[28]	耿其荣,刘冬耕,史艳侠,等. 浸润性乳腺癌近似分子亚型的临床意义[J]. 中山大学学报(医学科学版), 2009,30(4):458-462,467.

组别	ER阳性	PR阳性	HER-2阳性
DCIS组(n=52)	25(48.08)	19(36.54)	38(73.08)
IDC组(n=224)	152(67.86)	102(45.54)	121(54.02)
χ ²值	7.18	1.39	6.28
P值	0.01	0.24	0.01

组别	ER阳性	PR阳性	HER-2阳性
DCIS组(n=52)	25(48.08)	19(36.54)	38(73.08)
IDC组(n=224)	152(67.86)	102(45.54)	121(54.02)
χ ²值	7.18	1.39	6.28
P值	0.01	0.24	0.01

组别	luminalA型	luminalB型	HER-2阳性型	三阴性乳腺癌
DCIS组(n=52)	14(26.92)	11(21.16)	23(44.23)	4(7.69)
IDC组(n=224)	98(43.75)	55(24.56)	46(20.54)	25(11.16)
χ ²值	13.11
P值	0.00

组别	luminalA型	luminalB型	HER-2阳性型	三阴性乳腺癌
DCIS组(n=52)	14(26.92)	11(21.16)	23(44.23)	4(7.69)
IDC组(n=224)	98(43.75)	55(24.56)	46(20.54)	25(11.16)
χ ²值	13.11
P值	0.00

Please choose a citation manager

Content to export